Immune Fingerprints of the Patient may Help Diagnose Bacterial Infections and Guide Treatment

A patient's immune response may provide better and more rapid insights into the cause, prognosis and severity of certain bacterial infections than conventional tests.

This is according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Such an "immune fingerprint" could lead to more accurate diagnoses and more appropriate antibiotic treatment.

Reprogramming E. Coli to Combat Hard to Treat Bacterial Infections

The notorious bacteria E. coli is well known for making people sick. But scientists have reprogrammed the microbe, which also comes in harmless varieties, to make it seek out and fight other disease-causing pathogens.

Approximately 11% of kidney failure patients on dialysis receive peritoneal dialysis, which is home-based. Peritoneal dialysis is generally perceived as less burdensome and as effective as clinic-based hemodialysis, but infections can cause treatment failure and even patient death if not detected early. Unfortunately, current tests for infections—which use microbiological culture methods—are slow and inefficient. Fear of infection is the major reason for patients and their doctors to opt against peritoneal dialysis despite its otherwise potential clinical benefit.

Matthias Eberl, PhD, Nicholas Topley, PhD (Cardiff University, in the UK), and their colleagues wondered whether assessing dialysis patients' immune responses might help in the diagnosis of bacterial infections. They reasoned that the human body is capable of a rapid, sensitive, and specific detection of a broad spectrum of microbes, and each pathogen stimulates unique aspects of the immune system, essentially leaving a distinct "immune fingerprint."

Viral Vs. Bacterial Infections Accurately Sorted By Genomic Test

More than 90-percent accuracy in distinguishing between viral and bacterial infections when tested in people with respiratory illnesses was shown by a blood test developed by researchers.

For their study, the researchers recorded a range of microbiological, immunological, and clinical parameters from patients on the day they were admitted to the hospital for peritonitis, an infection of the abdominal cavity. "Our goal was to identify unique fingerprints that are associated with certain groups of pathogens and/or outcome that can be exploited for diagnostic and prognostic purposes," said Dr. Eberl.

The team found that certain immune markers correlated with microbiological test results and robustly predicted the presence of infection. Furthermore, particular combinations of these biomarkers also predicted the nature of the causative pathogen—discriminating between Gram-negative and Gram-positive infections—and identified patients at an elevated risk of experiencing treatment failure.

"To our knowledge, this is the first study in acutely infected patients exploiting the notion that microorganisms display distinct sets of pathogen-associated patterns and interact with the immune system in a unique and specific manner for diagnostic purposes," said Professor Topley. In addition to potentially improving the diagnosis and treatment of peritonitis in peritoneal dialysis patients, the findings may also be applicable to other local and systemic infections. Dr. Eberl added that "the data suggest that it may be possible to develop a simple fingerprint-based point-of-care test that can be used by a general practitioner—at the bed-side or at home—to ensure that the right treatment is given to each patient."

In an accompanying editorial, Marien Fieren, PhD (Erasmus Medical Center, in The Netherlands) noted that the study "deepens our understanding of the complex, local pathogen-host interactions. Such patient-based studies are important not only from a theoretical perspective but also for the prospect of future developments that could improve diagnosis and management of the various forms of peritonitis."

Source: Eurekalert

Font : A-A+

Henry Ford Hospital Study Finds Drug Approved For Treating Bacterial Infections Shows Promise for Treating MRSA Pneumonia

A Henry Ford Hospital study has found that a drug approved just two years ago for treating bacterial infections may hold promise for treating the potentially fatal MRSA pneumonia.

<< Microsatellite DNA Analysis Reveals Genetic Change of Malar...

Scientists Find A New Treatment for Patients at High Risk o... >>

Newborn Baby's Early Infection Linked to Bacterial Infection in Mother

Infection during a newborn's first 7 days of life known as early-onset neonatal infection is associated with bacterial infection or colonization in the mother.